Document is current
Any future updates will be listed below
-
Authors
Barrett, James E.
Herzog, Chiara https://orcid.org/0000-0002-1572-498X
Jones, Allison
Leavy, Olivia C. https://orcid.org/0000-0002-1503-5535
Evans, Iona
Knapp, Susanne
Reisel, Daniel
Nazarenko, Tatiana https://orcid.org/0000-0002-4245-7346
Kim, Yoo-Na https://orcid.org/0000-0002-0202-3228
Franchi, Dorella
Ryan, Andy
Franks, Joanna
Bjørge, Line
Zikan, Michal https://orcid.org/0000-0001-5266-8895
Cibula, David https://orcid.org/0000-0001-6387-9356
Harbeck, Nadia https://orcid.org/0000-0002-9744-7372
Colombo, Nicoletta
Dudbridge, Frank https://orcid.org/0000-0002-8817-8908
Jones, Louise
Sundström, Karin
Dillner, Joakim https://orcid.org/0000-0001-8588-6506
Rådestad, Angelique Flöter
Gemzell-Danielsson, Kristina https://orcid.org/0000-0001-6516-1444
Pashayan, Nora https://orcid.org/0000-0003-0843-2468
Widschwendter, Martin https://orcid.org/0000-0002-7778-8380
- License Information
-
More Information
Article History
Received: 20 May 2021
Accepted: 2 December 2021
First Online: 1 February 2022
Competing interests
: UCLB (UCL’s commercialisation company) has filed a patent (“Methods for detecting and predicting cancer”—Application Number N418732GB) on breast cancer detection and risk prediction as described in the paper—M.W. and J.E.B. are named as inventors on this patent. J.E.B., C.H. and M.W. are shareholders of Sola Diagnostics GmbH, which holds an exclusive licence to the intellectual property that protects the commercialisation of the WID-BC test. All other authors declare no competing interests relevant to the content of this manuscript.
